Rosiglitazone Increases Cerebral Klotho Expression to Reverse Baroreflex in Type 1-Like Diabetic Rats

Table 2

Baseline level of the blood glucose, mean arterial pressure (MAP) and heart rate (HR), bradycardic and tachycardic peak, and HR range in STZ rats receiving the rosiglitazone (TZD) or not.

Variable	Wistar	STZ	STZ + TZD
Blood glucose (mg/dL)	98 ± 3.7	367 ± 11.4***	361 ± 10.3***
MAP (mmHg)	109.8 ± 4.4	87.6 ± 5.7**	95.4 ± 7.3^*#
HR (bpm)	351 ± 8.3	287 ± 4.8***	316 ± 7.4^*#
Bradycardic peak (bpm)	248 ± 7.3	242 ± 6.2	245 ± 4.3
Tachycardic peak (bpm)	437 ± 8.5	363 ± 4.7**	392 ± 11.6^*#
HR range (bpm)	188 ± 8.2	123 ± 4.9**	142 ± 7.3^*#

Values (mean ± SE) were obtained from each group of eight rats. ^∗𝑃<0.05, ^∗∗𝑃<0.01, and ^∗∗∗𝑃<0.001 compared to Wistar. ^#𝑃<0.05 compared to STZ.